Idag medverkar Scandinavian Biopharma på Vaccines for Enteric Disease (VED) – en konferens där vacciner och deras förebyggande roll mot diarrésjukdomar står i fokus. Vi kommer att presentera mycket lovande resultat från genomförda och pågående kliniska studier av ETVAX®.
Today we will present the excellent results from multiple completed and on-going clinical trials of ETVAX® at VED - a conference that addresses the diverse aspects of vaccines to counter human enteric diseases. In the light of global public health issues, enteric diseases are estimated to be the top cause of infectious morbidity and the second leading cause of infectious mortality worldwide.
We are a part of the global movement to defeat diarrheal disease. That makes us proud!
”Etvax is the lead candidate in the field of ETEC”. Så sa Richard Walker under programpunkten ”Advances in ETEC and Shigella prevention throught vaccination” på International Society of Travel Medicin konferens, CISTM14, förra veckan.
Every year hundreds of thousands of people die from diarrhea caused by ETEC bacteria. A study published in Nature Genetics describes how the University of Gothenburg, our collaborators, have mapped the spread of ETEC strains around the world. It provides key information about how pathogenic bacteria arise, which will be important for our vaccine currently under development.
Varje år dör hundratusentals av diarrésjukdom som orsakats av ETEC-bakterier. I en studie som publiceras i Nature Genetics har vår samarbetspartner, Göteborgs universitet, kartlagt hur ETEC-bakteriens stammar sprids över världen. Studien ger viktig kunskap om hur sjukdomsframkallande bakterier uppstår vilket har betydelse för vårt diarrévaccin som är under utveckling.
In a recently published article in Vaccine the clinical phase I results with our new oral vaccine against ETEC is presented.The results show that the vaccine was safe, well tolerated and broadly immunogenic – a result that highly exceeded the expectations. The vaccine will be tested in a Phase I/II trials in Bangladesh during next year and in travelers to ETEC-endemic areas the year after.
I en nyligen publicerad artikel i Vaccine presenteras fas I resultat från studie med vårt nya orala vaccin mot ETEC. Resultaten visar att vaccinet var säkert, väl tolererat och ger ett brett immunsvar - ett resultat som med råge överträffade förväntningarna. Vaccinet under 2015 testas i en fas I/II-studie i Bangladesh och året därpå i resenärer till ETEC-endemiska områden.
Results from preclinical evaluation of the new multivalent, oral Traveler’s diarrhea vaccine was recently published.The vaccine was studied for immunogenicity and safety in mice and was well tolerated and induced a strong intestinal immune response to all vaccine components.